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BREAKING UP THE MONOTONY: PROTOCOL SPECIFIC PATIENT EDU-
CATION PATHWAYS
Rimkus, C.F.1 1Barnes-Jewish Hospital, St. Louis, MO.
Educating blood and marrow transplant (BMT) patients can be
challenging. The challenges include the need to communicate
complicated information coupled with the emotional aspect of a
life threatening treatment. An additional factor is the known cog-
nitive dysfunction encountered by patients receiving high dose
chemotherapy. This cognitive dysfunction has been described as
similar to attention deﬁcit disorder causing difﬁculty concentrating
and remembering information. Yet another challenge is the vari-
ability of information given by the nursing staff.
Given these challenges, the Clinical Nurse Specialist on a 26 bed
BMT unit initiated a systematic education process. A protocol
speciﬁc education pathway was developed for the most common
BMT protocols. The goal of an education pathway is to standard-
ize education as well as to distribute the education throughout the
hospital stay on a “need to know” basis. The day before a new
procedure, treatment, or medication is started, a teaching sheet is
given to the patient. The nurses review the teaching sheets with the
patients to ensure understanding. To streamline the process for the
nurses, packets are pre-assembled in the order of distribution and
on admission are placed on the patient’s working clipboard. All
teaching sheets have been calculated as written at a 6th grade or less
reading level. The education topics were purposely brief and to the
point having no more than four pages per subject.
Staff and patients have evaluated the new education process and
their suggestions for improvement have been incorporated. Pa-
tients feel that it is very helpful to get the information as needed
instead of all at one time. One patient commented that she knew
that if she received all sheets at once, she would have read it all but
not remembered anything. The nursing staff feels that the process
is easy and has standardized the education process. The use of
protocol speciﬁc education pathways is a unique way to educate
BMT patients resulting in beneﬁts to both patients and nursing
staff.
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CLINICAL PRACTICE REVIEW: UTILIZING EVIDENCED-BASED PRAC-
TICE TO DEVELOP STANDARDS OF CARE FOR THE IMMUNE-SUP-
PRESSED BLOOD AND MARROW TRANSPLANT (BMT) PATIENT ACROSS
CARE SETTINGS
Rimkus, C.F.1, O’Neill, S.1, Hendricks, D.1, Laub, L.1 1Barnes-Jewish
Hospital, St. Louis, MO.
Ensuring that care is consistent throughout the healthcare con-
tinuum can be challenging in a large cancer center. At one large
comprehensive cancer center, inconsistencies in care of immune-
suppressed patients existed among care settings. Each care setting
had variable practices for issues that patients daily encounter such
as, which patients can leave the nursing unit, who needs to wear a
mask at discharge, child visitors, what should be done with ﬂowers,
what prep if any should take place in the patient’s home, drinking
water, child visiting and supplements such as activated cultures.
Patients expressed confusion and frustration over the inconsisten-
cies. In an attempt to standardize practice across the care contin-
uum, the blood and marrow transplantation (BMT) Clinical Nurse
Specialist (CNS) initiated a meeting among the two inpatient
nursing units who care for BMT patients, the BMT coordinators,
the discharge coordinators, the infection control liaison and the
outpatient center who cares for the BMT patients post discharge.
The CNS reviewed the evidence-based literature on care of the
immune-suppressed BMT patient in various care settings as well as
reviewed the National Comprehensive Cancer Network (NCCN)
and Centers for Disease Control (CDC) guidelines for infection
control in BMT patients. The group looked at the evidence and
discussed the speciﬁc issues each care setting encountered. Con-
sistent guidelines that are evidenced based were adopted. The staff
in each care setting was educated using sample scripting. Printed
patient education material was also reviewed to ensure that it
reﬂected the newly established guidelines.
The group then identiﬁed the need to review the new evidence
on immunizing BMT patients set by the European Group for
Blood and Marrow Transplantation (EBMT). New immunization
recommendations were presented to the physician group and
adopted as well. The group was energized by the accomplishments
and opted to continue meeting bimonthly to review all practice
standards that cross the care continuum. This meeting not only
accomplished the desired endpoint to incorporate evidenced-based
practice across care settings, but it also brought the group together
collegially to discuss other practice issues.
407
PREDICTIVE FACTORS FOR ENGRAFTMENT IN BONE MARROW TRANS-
PLANT RECIPIENTS
Rivera, Z.P.1, Gulbis, A.M.1, de Lima, M.1, Rondon, G.1 1University of
Texas MD Cancer Center, Houston, TX.
Certain laboratory values may predict engraftment in hemato-
poietic stem cell transplant (HSCT) recipients. Hypophos-
phatemia and engraftment in hematopoietic stem cell transplanta-
tion is infrequently reported in the literature. The mechanism
believed to be associated with hypophosphatemia is phosphate
uptake by replicating cells. Raanani, et al. study evaluated the
interrelationship between cytokine release, the elevation in white
blood cell (WBC) count and development of hypophosphatemia
during the engraftment period. Results indicated that 62% (total of
60 patients) developed hypophosphatemia with minimal phospho-
rous levels on day 8 antedating engraftment by two days (Raa-
nani, et al.).
With the limited information on hypophosphatemia and its as-
sociation with engraftment, a retrospective study is being con-
ducted to analyze and assess data, which will look at laboratory
indicators that may predict engraftment in HSCT patients. A chart
review will be completed looking at 200 HSCT recipients during
the time period of January 2006 to May 2006.
The results will be presented to show how hypophosphatemia is
linked to predicting engraftment, which may help identify signs
and symptoms of serious infection (i.e. fever, rash), engraftment
syndrome/cytokine storm (i.e. shortness of breath, erythema, and
increased oxygen requirements), and hyperacute graft versus host
disease. The data collected will assist the medical team and nursing
staff to determine appropriate therapy and outcomes.
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DEVELOPMENT OF A “LIVER BIOPSY AND MANAGEMENT PLAN OF
CARE” FOR HEMATOPOIETIC STEM CELL TRANSPLANT PATIENTS
Sirilla, J.A.1, Krugh, D.1, Ohr, M.1, Devine, S.M.1 1Ohio State
University James Cancer Hospital & Solove Research Institute, Colum-
bus, OH.
Although a liver biopsy is an important diagnostic tool after
allogeneic Hematopoietic Stem Cell Transplant (HSCT), it is a
high-risk procedure that may result in signiﬁcant complications.
The BMT Program at the OSU James Cancer Hospital developed
a Plan of Care that provides guidelines for indications, pre-proce-
dure laboratory testing, the acceptable laboratory results range for
transjugular and percutaneous procedures, and post-procedure
management of liver biopsies in HSCT patients.
The indications for a liver biopsy include:
 GvHD (Graft versus Host Disease) versus VOD (venous occlu-
sive disease)
 Mixed response and/or no response to treatment
 Chronic GvHD versus iron overload or viral infection
 Hepatitis C and/or B carriers with suspected liver GvHD
The transjugular approach is recommended, especially when the
patient has thrombocytopenia and is refractory to platelet transfu-
sions, a coagulopathy and/or ascites. Patients with a creatinine level
 1.5 mg/dl require a nephrotoxicity pre-medication protocol
24-48 hours prior to a transjugular liver biopsy. The following
laboratory tests are recommended for all patients on the morning
of the procedure: Platelet Count, PT/ PTT, INR, Fibrinogen, and
Type and Screen.
Following the procedure, the nurse assesses vital signs, pain, and
evidence of bleeding every 15 minutes for 1 hour then every 30
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